Warfarin and pharmacogenomic testing: the case for restraint.
Garcia
D A
DA
Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. davgarcia@salud.unm.edu
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005820:Genetic Testing / Q000706:statistics & numerical data*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010597:Pharmacogenetics; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases